Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

AstraZeneca Acquires EsoBiotec for $1 Billion to Strengthen Cell-Therapy Portfolio

by Team Lumida
March 17, 2025
in Biotech, Markets
Reading Time: 3 mins read
A A
0
vitamin b 12 100 mg

Photo by Mika Baumeister on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • AstraZeneca will pay $425 million upfront, with an additional $575 million tied to milestones.
  • The acquisition includes EsoBiotec’s innovative in vivo cell therapy platform.
  • The deal is expected to close in Q2 2025 and will not impact AstraZeneca’s 2025 financial guidance.
  • This move positions AstraZeneca to expand its presence in the growing cell-therapy market.

What Happened?

AstraZeneca announced the acquisition of Belgian biotech company EsoBiotec in a deal valued at up to $1 billion. The British pharmaceutical giant will pay $425 million upon closing, expected in the second quarter of 2025, and up to $575 million in milestone payments. The acquisition includes EsoBiotec’s in vivo cell therapy platform, which modifies immune cells directly within the patient’s body, potentially improving accessibility and reducing treatment costs.

Why It Matters?

This acquisition underscores AstraZeneca’s strategic focus on expanding its cell-therapy portfolio, a rapidly growing area in biotechnology. The in vivo cell therapy platform offers a significant advantage by eliminating the need for complex manufacturing processes, which could lower costs and broaden patient access. For investors, this move highlights AstraZeneca’s commitment to innovation and its ability to compete in cutting-edge therapeutic areas, potentially driving long-term growth.

What’s Next?

The deal is expected to close in Q2 2025, with AstraZeneca focusing on integrating EsoBiotec’s technology into its pipeline. Investors should monitor the progress of regulatory approvals and milestone achievements, as these will determine the full financial impact of the acquisition. Additionally, AstraZeneca’s ability to commercialize this platform effectively will be a key factor in its success in the cell-therapy market.

Source
Previous Post

Nvidia Gains on Strong AI Demand Signals from Key Supplier Foxconn

Next Post

Nvidia’s AI Event Sparks Gains for Asian Suppliers as Next-Gen Chips Drive Market Optimism

Recommended For You

Goldman Sachs Warns of Risks for Lower-Quality Stocks Amid Market Rally

by Team Lumida
1 hour ago
Goldman Sachs Urges Investors to Cut Risk: Is a Selloff Looming?

Key Takeaways: Powered by lumidawealth.com Goldman Sachs Managing Director Louis Miller cautioned that lower-quality stocks, including non-profitable tech and meme stocks, face significant downside risks despite the broader market...

Read more

FedEx Shares Mixed Outlook as Tariffs and Weak International Demand Weigh on Growth

by Team Lumida
1 hour ago
FedEx Shares Mixed Outlook as Tariffs and Weak International Demand Weigh on Growth

Key Takeaways: Powered by lumidawealth.com FedEx expects flat to 2% revenue growth in its fiscal first quarter, with earnings per share projected at $2.90 to$3.50*, below analysts’ expectations of...

Read more

Tesla’s EU Sales Plunge 40.5% in May Amid Rising EV Market Competition

by Team Lumida
2 hours ago
blue coupe parked beside white wall

Key Takeaways: Powered by lumidawealth.com Tesla’s new-car registrations in the EU fell 40.5% in May, continuing a streak of monthly declines since December, despite a 25% growth in the...

Read more

AstraZeneca’s Datroway Receives U.S. Approval for Non-Small Cell Lung Cancer Treatment

by Team Lumida
1 day ago
AstraZeneca’s Datroway Receives U.S. Approval for Non-Small Cell Lung Cancer Treatment

Key Takeaways: Powered by lumidawealth.com AstraZeneca’s Datroway has been approved in the U.S. to treat adult patients with non-small cell lung cancer who have already undergone chemotherapy. The approval...

Read more

U.K. Antitrust Authority Proposes Strategic Market Status for Google in Search and Advertising

by Team Lumida
1 day ago
Google’s Bold AI Bet: Transforming Healthcare After Costly Missteps

Key Takeaways: Powered by lumidawealth.com The U.K.’s Competition and Markets Authority (CMA) has proposed designating Google as having strategic market status in general search and search advertising. If confirmed,...

Read more

Tesla Launches Robotaxi Service in Austin, Paving the Way for Autonomous Ride-Hailing Expansion

by Team Lumida
2 days ago
blue coupe parked beside white wall

Key Takeaways: Powered by lumidawealth.com Tesla has launched its robotaxi service in Austin, Texas, with up to 20 Model Y vehicles operating autonomously within a geofenced area. The service...

Read more

Walmart to Pay$10 Million to Settle FTC Lawsuit Over Money Transfer Fraud

by Team Lumida
2 days ago
Walmart Expands Logistics Services Beyond Its Marketplace: What This Means for Investors

Key Takeaways: Powered by lumidawealth.com Walmart has agreed to pay $10 million* to settle a U.S. Federal Trade Commission (FTC) lawsuit accusing it of ignoring fraudsters who used its...

Read more

Trump Grants TikTok a Third 90-Day Reprieve Amid National Security Concerns

by Team Lumida
5 days ago
red and whites logo

Key Takeaways: Powered by lumidawealth.com President Trump issued another 90-day extension for TikTok, delaying enforcement of a 2024 law requiring the app’s sale or shutdown over national security concerns....

Read more

Baidu’s Apollo Go Targets Singapore and Malaysia for Robotaxi Expansion by 2025

by Team Lumida
5 days ago
Baidu Unveils Ernie X1 AI Model to Rival DeepSeek at Half the Cost

Key Takeaways: Powered by lumidawealth.com Baidu’s Apollo Go, the largest Chinese robotaxi fleet, plans to expand into Southeast Asia, focusing on Singapore and Malaysia by the end of 2025....

Read more

Vodafone Appoints Microsoft’s Pilar López as New CFO Amid Turnaround Efforts

by Team Lumida
6 days ago
Vodafone Appoints Microsoft’s Pilar López as New CFO Amid Turnaround Efforts

Key Takeaways: Powered by lumidawealth.com Pilar López, a senior Microsoft executive with extensive experience at Telefonica, will join Vodafone as CFO designate in October and officially take over on...

Read more
Next Post
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia’s AI Event Sparks Gains for Asian Suppliers as Next-Gen Chips Drive Market Optimism

China’s Economic Struggles: Factory Activity Falls Again

China Starts 2025 with Strong Economic Momentum Amid Rising U.S. Tariffs

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Geopolitical Shockwave: U.S. Stocks Fall, Oil Prices Spike After Iran Strikes Israel

October 2, 2024
small kid standing on planked footpath

Global Baby Bust: Why Falling Birthrates Are a Red Flag for Investors

May 17, 2024

Coinbase Dips 8% on CME Bitcoin News

May 17, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018